Comparing TuHURA Biosciences (NASDAQ:HURA) & Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Insider & Institutional Ownership

0.6% of TuHURA Biosciences shares are owned by institutional investors. 4.3% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Agios Pharmaceuticals and TuHURA Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-895.86%	-28.35%	-26.42%
TuHURA Biosciences	N/A	-196.68%	-123.41%

Valuation and Earnings

This table compares Agios Pharmaceuticals and TuHURA Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$36.50 million	45.59	$673.72 million	($7.00)	-4.08
TuHURA Biosciences	N/A	N/A	-$21.68 million	($0.50)	-1.34

Agios Pharmaceuticals has higher revenue and earnings than TuHURA Biosciences. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Agios Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Agios Pharmaceuticals and TuHURA Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1	4	6	0	2.45
TuHURA Biosciences	1	0	2	1	2.75

Agios Pharmaceuticals presently has a consensus price target of $39.44, suggesting a potential upside of 38.21%. TuHURA Biosciences has a consensus price target of $9.00, suggesting a potential upside of 1,247.91%. Given TuHURA Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe TuHURA Biosciences is more favorable than Agios Pharmaceuticals.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

About TuHURA Biosciences

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.